Medical Science Liaison, Oncology, Lung & Emerging Tumors (Central & North Texas) at Bristol-Myers Squibb

Dallas, Texas, United States

Bristol-Myers Squibb Logo
Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, OncologyIndustries

Requirements

Candidates must possess an advanced degree (MD, PharmD, PhD) in a relevant scientific or clinical discipline. A minimum of 3 years of experience in a medical science liaison or similar role within the pharmaceutical industry, specifically in oncology, is required. Demonstrated ability to engage in peer-to-peer scientific dialogue with healthcare professionals and thought leaders is essential. Experience with lung cancer and emerging tumor types is highly preferred.

Responsibilities

The Medical Science Liaison will build relationships with academic and community thought leaders in oncology through scientific dialogue, utilizing various interaction channels. They will engage with healthcare professionals to gain insights into the clinical landscape, contributing to the development of medical plans for product launches and lifecycle management. Responsibilities include collaborating with medical societies, patient advocacy groups, and guideline committee members, as well as providing training for external speakers. The MSL will also serve as a scientific and clinical advisor to internal teams, ensuring alignment with enterprise medical strategies and facilitating patient access to BMS medicines by educating the medical community on their safe and effective use. This role involves addressing scientific questions beyond approved indications and may include 'Medical on Call' duties to answer unsolicited questions from treating physicians.

Skills

Medical Science Liaison
Scientific Communication
Clinical Expertise
Medical Consulting
Peer-to-peer Communication

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI